SRC and chronic myelogenous leukemia, BCR-ABL1 positive: Dasatinib, a highly potent second-generation adenosine triphosphate-competitive inhibitor shown to be effective against multiple protein tyrosine kinases, including platelet-derived growth factor receptor (PDGFR) and the Src family of kinases 30, has been approved for pediatric chronic myeloid leukemia by the FDA 31.